[关键词]
[摘要]
目的 对临床上常用、经济有效的口服钙拮抗剂降压药进行药物经济学评价,为合理用药提供借鉴。方法 采用回顾性文献计量分析的方法,检索中英文数据库中2003-2015年发表的与钙拮抗剂降压药相关的药物经济学评价文献,利用纳入排除标准筛选后,对其方法学和质量进行评述。结果 以国家统计局报告的2014年我国人均GDP为外部参考值,将硝苯地平作为对照药品,非洛地平、氨氯地平、硝苯地平缓释片、硝苯地平控释片的增量成本效果比值均在451~8 543元,均小于人均GDP。结论 《中国高血压防治指南》推荐的药物、但《国家基本药物目录》(2012版)中尚未收载的硝苯地平控释片、左旋氨氯地平、非洛地平均具有一定经济性。
[Key word]
[Abstract]
Objective To provide reference for the clinical treatment of anti-hypertensive drugs associated with calcium antagonists by methods of retrospective analysis of literature. Methods In this study, the literature on the economic evaluation of the drugs associated with calcium antagonists during the period from 2003 to 2015 were searched, and then the methods and quality of the literatures were reviewed. Results The incremental cost effectiveness ratio of Felodipine, Amlodipine, Nifedipine sustained release tablets, and Nifedipine controlled release tablets were between 451 to 8 543 yuan and less than per capita GDP in 2014 with Nifedipine controlled release tablets as the control drug. Conclusion Nifedipine controlled release tablets, amlodipine, and Felodipine recommended by Chinese Hypertension Prevention Guide are economical, but have not yet been received by the National Essential Drug List (2012 Edition).
[中图分类号]
[基金项目]
中国博士后科学基金资助项目(2014M561196);天津医科大学科学基金项目(2014KYRQ04)